Despite their potential to change the face of medicine, reducing long-term medical costs and curing diseases, innovations in cell and gene therapy face regulatory issues, along with the need for long-term studies, before market acceptance can be achieved.
Research in this important field is undergoing rapid growth. However, due to the significant costs and timescales involved in gaining approval, effective IP strategies must be established to protect investment and maintain market position.
Working across academic research institutes, SMEs and large multinationals, HGF’s specialist cell and gene therapy attorneys tap into their vast experience to develop robust and tailored IP strategies for their clients in this field. The team has extensive experience in helping organisations protect and exploit their IP and assess their freedom to operate.
IAM Patent 1000 the world’s leading patent professionals 2023 guide has now been published and we are delighted to have 31 attorneys recognised as world-class individuals in the guide. The …Read article
The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …Read article
The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …Event details
HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …Event details
Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …Read article
HGF is a gold sponsor at the BioCap Conference 2022. The conference will be held on Thursday 22 September at the Alderley Park Conference Centre. It connects life sciences businesses, …Event details
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details